share_log

Citigroup Maintains Neutral on Acelyrin, Lowers Price Target to $3

Benzinga ·  Jan 7 19:58  · Ratings

Citigroup analyst Samantha Semenkow maintains Acelyrin (NASDAQ:SLRN) with a Neutral and lowers the price target from $6 to $3.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment